Q4FY25 earnings impact: Aarti Drugs shares up 14% on profit growth, MGL and KEI shares higher up to 4%

Shares of Aarti Drugs soared 14 percent on May 7 following the Q4FY25 earnings, with Mahanagar Gas (MGL) and KEI Industries' shares too recording a strong rise in response to quarterly earnings.

Aarti Drugs Q4 Results

Aarti Drugs shares surged 14 percent in response to the company's March quarter results released post market hours of May 6. The pharma company's net profit jumped 33 percent on year to Rs 62.86 crore in Q4FY25. The revenue from operations rose over 9 percent YoY to Rs 676.76 crore. EBITDA rose 10 percent YoY to Rs 95.2 crore, while EBITDA margin stood at 14 percent.

"FY25 was a challenging year, beginning with muted global demand and elevated raw material costs, which impacted overall performance. Greater than expected market volatility, particularly due to falling input prices, led to a 5% on-year revenue decline. Despite the challenges, the company improved cost efficiency and operational discipline over the year, which helped maintain our EBITDA margin at 12.6%. The margin performance improved significantly in H2FY25, driven by stabilization in input costs," said Aarti Drugs' CFO and COO, Adhish Patil.